Varian Medical (NYSE:VAR) said today it won Brazilian ANVISA clearance for its Halcyon image-guided volumetric intensity modulated radiotherapy cancer treatment system.
The Palo Alto, Calif.-based company said its Halcyon IMRT system features improvements that make it more comfortable for patients and streamline operator’s workflow, only requiring nine steps from start to treatment, down from 30 steps in legacy machines.
Varian Medical said the device is designed to handle “the majority” of cancer patients, including individuals with prostate, breast, head & neck and other forms of cancer.
“Halcyon is engineered to revolutionize the clinical workflow and advance cost-effective cancer care worldwide. With ANVISA registration, clinicians in Brazil now have access to this new technology and we look forward to continuing our close collaboration with them in the global fight against cancer,” oncology systems biz prez Kolleen Kennedy said in a press release.
In November, Varian Medical said it opened a new regional facility in Jundiai, Brazil.
